Ce diaporama a bien été signalé.
Le téléchargement de votre SlideShare est en cours. ×

Cyrcadia Health - Health & Wearable Singapore 2015 - The Propell Group

Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité
Publicité

Consultez-les par la suite

1 sur 16 Publicité
Publicité

Plus De Contenu Connexe

Diaporamas pour vous (20)

Similaire à Cyrcadia Health - Health & Wearable Singapore 2015 - The Propell Group (20)

Publicité

Cyrcadia Health - Health & Wearable Singapore 2015 - The Propell Group

  1. 1. The Internet of Things (IoT) Wearable Breast Cancer Screening Enabling personalized wellness screening through telemedicine and improved patient access 1
  2. 2. 2 Julien de SALABERRY Experienced regional head and GM. 15+ years in healthcare with leading brands including Eli Lilly, Boston Scientific, Baxter, GSK, Merck & Co. Significant Asia Pacific Experience. The Propell Group is a boutique venture investor and adviser firm focused on early stage companies in healthcare technology Co-Author of iDisrupted Founder & CIO Ÿ The Propell Group M: +65 9488 7334 julien@propellgroup.biz @enquirepropell 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  3. 3. •  Breast cancer is the 2nd most common cancer in the world and, by far, the most frequent cancer among women with an estimated 1.67 million new cancer cases diagnosed in 2012 (25% of all cancers) •  Early detection screenings are critical to saving lives, but often fail to catch the disease before it’s too late 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential 2 Quick Facts
  4. 4. The Innovation A bra insert. Using sensor technology connected to the Internet, this bra can detect the earliest signs of breast cancer. Much like a Holter monitor, sensors detect circadian metabolic changes over time which are associated with breast cancer. This wearable technology and the data it collects, represents the power and potential of Connected Wearable Devices. 32015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  5. 5. Wearable Grid (2 to 24 hours) What We Do Patient and/or Doctor Big Data Cancer Analytics VS. Mammography Compression/Radiation 5 Cyrcadia Health Proprietary Collection Grid manufactured by: Smart Device Enabled Monetizable Global Breast Cancer Database 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  6. 6. Greatly Improved Dense Tissue Screening Accuracy Significant Reduction in Unnecessary Biopsy Procedures 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 77% 71% 20% % of False Positive Findings True Cancer Non-Cancerous Biopsies 83% 83% 60% 83% 48% 83% MAMMOGRAPHY CYRCADIA HEALTH % Accuracy Fatty Tissue Moderate Density High Density Key Medical Improvements •  1.2M biopsies on normal tissue @ $1,500 average cost occurs as a result of mammography annually •  57% improvement by CH = $1.026B Annual Savings and 684,000 less biopsies in the US •  Women with dense breast tissue have a significantly higher propensity for cancer •  Mammography accuracy is greatly reduced with density, down to 48% accuracy with the densest of tissue •  Cyrcadia provides a tissue agnostic solution 6 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  7. 7. 1.  Personalized Medical Health Care Screening –  Automated discrete physician alert to early cancer state –  Dense tissue screening alternative for 45% of female population –  Additive screening source to reduce 80% unnecessary biopsies 2.  Replaces Monthly Self Breast Health Exam –  Non-compressive, non-irradiative screening –  Home-based breast screening for earliest possible detection –  Connected health to physician, family and friends ensures use 3.  Cyrcadia Health Breast Cancer Research Portal –  Global breast cancer screening BIG Database is highly valuable to insurance, research, medical industry and university settings –  Early detection data combined with existing commercial databases will yield greater understanding of cancer inception and treatment alternatives Why Cyrcadia Health 7 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  8. 8. The Product Roadmap Correlation Sensor Grid Clinical Trials Life Science (Hospital) – Screening Wellness (Over The Counter) - Screening Life Science – Localization Correlation Sensor Grid Correlation Sensor Grid Localization Sensor Grid 8 Screen Normal/Abnormal Finding Original FDA 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  9. 9. 9 •  Global Genotype / Phenotype Differential •  Familial History Trending •  % Patient Increase via. Personalized Screening •  Global Fatty vs. Dense Breast Tissue Data •  Earliest Predictive Outcomes – All Ages •  Earliest Biomarker Indication Coordination Cancer Research Portal Cyrcadia Health Data Repository *Reference 23andME Recent Partnership with Genentech / Pfizer and 13 others The Value is in the Data* Interested Insurance Partners Allianz – Germany Apollo Munich – India Industry UniversityGovernment 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  10. 10. Ø  5 Years of Predictive Analytics Research Ø  3 Patents Issued in 2012 for Analytics Ø  500 Historical Patient Trials Completed Ø  Original FDA 510K Clearance Achieved Our Foundation 10 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  11. 11. How We Do…Machine Learning Big Data Cancer Analytics Engine Computational Intelligence leverages data sets and statistical algorithms to create models that predict future outcomes Case Data Collection Training Data Aggregation •  Historically collected clinical data– Demographics, Circadian Breast Cancer Profile (Predictive Attributes), Biopsy Results (Target Outcome) •  Preprocess Data – handle univariate and multivariate outliers Model Development •  Develop the best model that most accurately relates the predictive attributes and the target outcome •  Extract the Predictive Attributes - Demographics, Circadian Breast Cancer Profile Cyrcadia Library New Case Case Characterization •  Apply the best model derived from the training data on the case predictive attributes and determine the outcome (cancerous/non- cancerous) Performance Capture •  Calculate prediction accuracy •  Populate big data cancer database •  Improve the current model with the new data – More data => better model tuning => higher prediction accuracy! 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  12. 12. Ø  $26B Medical Device Manufacturer Ø  Largest Supplier of Wearable Devices Globally Ø  ISO 13485 and FDA Certified Ø  Intensely Focused on Timing and Deliverables – Excellent Partnership Ø  Clinical Validation Product Released – 10/2014 Ø  Commercial Product Release – Prototype projected 8/2016 Product Development 12 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  13. 13. Ø Complies with FDA Early Feasibility Investigational Device Exemption Ø Projecting H2 2016 FDA Clearance Ø  173 BI-RADS 4/5 Patient Trial Ø  To Begin Q2 2015 Ø  Project 4-6 Months for Initial Trial 2015 US Final Validation Trial 13 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  14. 14. Asia / European Union 1. CE Regulatory Process - Defined Time line - Earliest Revenue Pathway - Significant Need Exists 2. Distribution Established - Key Clinical Support Established 3. Interested Insurance Providers - Apollo Munich Well Care - Allianz Asian Wellness Link 4. Breast Cancer is #1 Epidemic - Represents Highest Cancer Mortality for All Women in Asia 5. Immediate High Scan Volume - Improved Geno/Phenotype Valuation to CH Cancer Library - Significant Value-add to Global Valuation of CH Core Lab Data North America 1. FDA Regulatory Clearance - FDA Improved Process - Driving to Keep Innovation in US - Out of Pocket Less than Mammo 2. US Density Legislation has no screening solution - Affects 50% of the Population 3. $1.6B current market exists for improved biopsy screening - 1.2M Unnecessary Biopsies/yr. 4. Monthly breast exam suggested by ACS - Effective Screening Solution Non-existent Today - Early Cancer Detection is Key to Improved Survival Rates Insurance Reimbursement 1. Dense Tissue Screening Precedent CPT Codes - 76645 Ultrasound/Mammo - Cyrcadia Dense Tissue - CH Screening Impacts 50% of Female Population - Pending FDA Clearance 2. Improved Surgical Outcomes Precedent CPT Codes - 77061 Tomosynthesis/Mammo = 6% Reduction in Biopsy Rate - With Cyrcadia + Mammo = 50%+ Reduction in Biopsy Rate 14 Global Launch Sequence H1 2016 H2 2016 H2 2016 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  15. 15. Na#onal  University  Hospital   Singapore   LIMITED VALIDATION TRIALS Q4 2015 - Q1 2016 LAUNCH •  TARGETED SCREENING TRIAL AGE 65 AND UP – NATIONAL UNIVERSITY HOSPITAL (NUH), SINGAPORE –  INTEREST IN PER1 / PER2 REDUCED EXPRESSION IN PRESENCE OF FAMILIAL OR GENETICALLY PREDISPOSED •  DIRECTED TOWARD ASIAN BREAST CANCER CONSORTIUM – 7 COUNTRIES PARTICIPATING: –  SG, MY, INDO, PH, KR, IN & BRUNEI •  MASS RANDOM SCREENING TRIAL Q4 2015 – APOLLO HOSPITALS, CHENNAI INDIA •  DISTRIBUTION ESTABLISHED IN SE ASIA, AUSTRALIA AND THE EUROPEAN UNION –  Advanced Medical Systems in SG Apollo  Hospital  Group   India   Commercial Launch – Asia 15 2015 Cyrcadia Health - www.cyrcadiahealth.com - Proprietary & Confidential
  16. 16. Thank  you  &  Apologies   Rob Royea – CEO rroyea@cyrcadiahealth.com (408) 334-3496 16

×